Complexed Prostate Specific Antigen Density is Better Than the Other PSA Derivatives for Detection of Prostate Cancer in Men with Total PSA between 2.5 and 20ng/ml: Results of a Prospective Multicenter Study
- 30 October 2004
- journal article
- clinical trial
- Published by Elsevier in European Urology
- Vol. 47 (3) , 302-307
- https://doi.org/10.1016/j.eururo.2004.10.009
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6–4.0 ng/mL range of total PSABJU International, 2004
- VARIATION IN PROSTATE SPECIFIC ANTIGEN RESULTS FROM 2 DIFFERENT ASSAY PLATFORMS: CLINICAL IMPACT ON 2,304 PATIENTS UNDERGOING PROSTATE CANCER SCREENINGJournal of Urology, 2004
- Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical TrialJournal of Urology, 2003
- A Multicenter Clinical Trial On the Use of Complexed Prostate Specific Antigen in Low Prostate Specific Antigen ConcentrationsJournal of Urology, 2003
- Biology of Prostate-Specific AntigenJournal of Clinical Oncology, 2003
- Robustness of Free Prostate Specific Antigen Measurements to Reduce Unnecessary Biopsies in the 2.6 to 4.0 ng./ml. RangeJournal of Urology, 2002
- Prostate specific antigen complexed to α‐1‐antichymotrypsin in patients with intermediate prostate specific antigen levelsCancer, 2002
- Incidence in Izmir in 1993–1994: first results from Izmir Cancer RegistryEuropean Journal Of Cancer, 2001
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histologyUrology, 1996